Table 1.
Characteristics of Patients and COVID-19 Vaccine Acceptability
| Variables | Total N (%) | Intention to receive COVID-19 vaccine | P value | |||
|---|---|---|---|---|---|---|
| No N (%) | Undecided N (%) | Yes N (%) | Yes vs. no | Yes vs. undecided | ||
| Total, N (%) | 119 | 64 (54) | 19 (16) | 36 (30) | ||
| Gender | 0.04 | 0.25 | ||||
| Female | 50 (42) | 31 (62) | 8 (16) | 11 (22) | ||
| Male | 69 (57.9) | 33 (47.8) | 11 (15.9) | 25 (36.2) | ||
| Age (median 64y, IQR [54.5–73.5]) | 0.31 | 0.40 | ||||
| 18–34y | 7 (5.8) | 5 (71.4) | 0 (0) | 2 (28.5) | ||
| 35–49y | 16 (13.5) | 10 (62.5) | 3 (18.7) | 3 (18.7) | ||
| 50–74y | 69 (57.9) | 34 (49.2) | 13 (18.8) | 22 (31.8) | ||
| > 75y | 27 (22.6) | 15 (55.6) | 3 (11.1) | 9 (33.3) | ||
| Health insurance | <0.01 | 0.03 | ||||
| Medicare or Medicaid | 53 (44.5) | 37 (69.8) | 6 (11.3) | 10 (18.8) | ||
| Private insurance | 46 (38.6) | 21 (45.65) | 11 (23.9) | 14 (30.4) | ||
| Uninsured | 20 (16.8) | 6 (30) | 2 (10) | 12 (60) | ||
| Comorbidities | ||||||
| Asthma | 15 (12.6) | 9 (60) | 2 (13.3) | 4 (26.7) | 0.07 | 0.12 |
| Coronary artery disease | 25 (21.1) | 16 (64) | 3 (12) | 6 (24) | 0.02 | 0.35 |
| Cancer | 9 (7.6) | 5 (55.6) | 2 (22.2) | 2 (22.2) | 0.18 | 0.26 |
| Congestive heart failure | 24 (20.2) | 16 (66.7) | 3 (12.5) | 5 (20.8) | <0.01 | 0.79 |
| Chronic kidney disease stage 3 and above | 14 (11.7) | 9 (64.2) | 2 (14.3) | 3 (21.4) | 0.03 | 0.47 |
| Chronic obstructive pulmonary disease | 17 (14.9) | 10 (58.8) | 2 (11.7) | 5 (29.4) | 0.05 | 0.27 |
| Cerebrovascular accident | 11 (9.2) | 7 (63.6) | 0 (0) | 4 (36.6) | 0.11 | 0.36 |
| Diabetes mellitus | 39 (32.7) | 24 (61.5) | 5 (12.8) | 10 (25.6) | <0.01 | 0.04 |
| HIV/AIDS | 5 (4.2) | 0 (0) | 0 (0) | 5 (100) | - | - |
| Hypertension | 68 (57.4) | 36 (52.9) | 10 (14.7) | 22 (32.5) | <0.01 | <0.01 |
| Obstructive sleep apnea | 8 (6.7) | 4 (50) | 2 (25) | 2 (25) | 0.08 | 0.49 |
| No of comorbidities | 0.30 | 0.02 | ||||
| No comorbidities | 22 (18.4) | 13 (59.1) | 2 (9.1) | 7 (31.8) | ||
| ≥ 1 comorbidity | 97 (81.5) | 51 (52.6) | 17 (17.5) | 29 (29.9) | ||
| Body mass index (BMI) | 0.13 | 0.41 | ||||
| < 30 kg/m2 | 54 (45.4) | 25 (46.3) | 9 (16.7) | 20 (37.4) | ||
| ≥ 30 to < 35 kg/m2 | 8 (6.7) | 4 (50) | 1 (12.5) | 3 (37.5) | ||
| ≥ 35 kg/m2 | 57 (47.9) | 35 (61.4) | 9 (15.8) | 13 (22.8) | ||
| Current tobacco use | 0.25 | 0.57 | ||||
| No | 78 (65.5) | 41 (52.5) | 13 (16.7) | 24 (30.7) | ||
| Yes | 41 (34.5) | 23 (56.1) | 6 (14.6) | 12 (29.2) | ||
χ2 tests were used to estimate associations between participant characteristics and intention to receive COVID-19 vaccine. 2 separate χ2 tests and associated P values were calculated to better distinguish characteristics associated with responses of “yes” versus “no” and characteristics associated with responses of “yes” versus “undecided”